A fluorescence-based in vitro assay for drug interactions with breast cancer resistance protein (BCRP, ABCG2)

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 72, Issue 3, 2009, Pages 605-613

  Mahringer, Anne ^a   Delzer, Jürgen ^b   Fricker, Gert ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ABBOTT GMBH AND CO KG   (Germany)

Author keywords

ABC protein; ABCG2; BCRP; Fluorescence assay; Mitoxantrone

Indexed keywords

4 AMINOHIPPURIC ACID; ASCORBIC ACID; BREAST CANCER RESISTANCE PROTEIN; CYCLOSPORIN A; CYTOSTATIC AGENT; DAIDZEIN; DIGOXIN; ELACRIDAR; ESTRADIOL; ESTRONE SULFATE; FLAVONOID; FUMITREMORGIN C; GENISTEIN; HOE 33342; KO 143; LEUKOTRIENE C4; LOPINAVIR; MITOXANTRONE; NARINGENIN; NICARDIPINE; NOVOBIOCIN; PHEOPHORBIDE; PROBENECID; PROTEIN INHIBITOR; SAQUINAVIR; TARIQUIDAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VERAPAMIL; VERLUKAST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; CELL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOTHELIUM CELL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MONOLAYER CULTURE; NONHUMAN; PROTEIN EXPRESSION; SCREENING; SWINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BORON COMPOUNDS; CELL LINE; CELL SEPARATION; CELL SURVIVAL; CELLS, CULTURED; DOGS; DRUG INTERACTIONS; DRUG RESISTANCE, MULTIPLE; FEMALE; FLOW CYTOMETRY; FLUORESCENT DYES; HUMANS; NEOPLASM PROTEINS; RATS; SWINE;

EID: 67549112082     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.01.010     Document Type: Article

References (79)

1. Takano M., Yumoto R., and Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol. Ther. 109 (2006) 137-161
2. Girardin F. Membrane transporter proteins: a challenge for CNS drug development. Dial. Clin. Neurosci. 8 (2006) 311-321
3. Kusuhara H., and Sugiyama Y. ATP-binding cassette, subfamily G (ABCG family). Pflugers Arch. 453 (2007) 735-744
4. Velamakanni S., Wei S.L., Janvilisri T., and van Veen H.W. ABCG transporters: structure, substrate specificities and physiological roles: a brief overview. J. Bioenerg. Biomembr. 39 (2007) 465-471
5. Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., and Ross D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 22 (1998) 15665-15670
6. Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., and Bates S.E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes. Cancer Res. 59 (1999) 8-13
7. Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., and Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58 (1998) 5337-5339
8. Ifergan I., Shafran A., Jansen G., Hooijberg J.H., Scheffer G.L., and Assaraf Y.G. Folate deprivation results in the loss of breast cancer resistance protein (BCRP/Bcrp) expression. A role for BCRP in cellular folate homeostasis. J. Biol. Chem. 279 (2004) 25527-25534
9. van Herwaarden A.E., Jonker J.W., Wagenaar E., Brinkhuis R.F., Schellens J.H., Beijnen J.H., and Schinkel A.H. The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Res. 63 (2003) 6447-6452
10. van Herwaarden A.E., Wagenaar E., Merino G., Jonker J.W., Rosing H., Beijnen J.H., and Schinkel A.H. Multidrug transporter Bcrp/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk. Mol. Cell Biol. 27 (2007) 1247-1253
11. Bailey-Dell K.J., Hassel B., Doyle L.A., and Ross D.D. Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene. Biochim. Biophys. Acta 1520 (2001) 234-241
12. Henriksen U., Gether U., and Litman T. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter Bcrp. J. Cell Sci. 118 (2005) 1417-1426
13. Bhatia A., Schäfer U.H.J., and Hrycyna C.A. Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers. Biochemistry 44 (2005) 10893-10904
14. Kage K., Tsukahara S., Sugiyama T., Asada S., Ishikawa E., Tsuruo T., and Sugimoto Y. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer 97 (2002) 626-630
15. Ross D.D., Karp J.E., Chen T.T., and Doyle L.A. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia 96 (2000) 365-368
16. Fetsch P.A., Abati A., Litman T., Morisaki K., Honjo Y., Mittal K., and Bates S.E. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett. 235 (2006) 84-92
17. Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., van De Vijver M.J., Scheper R.J., and Schellens J.H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61 (2001) 3458-3464
18. Allen J.D., and Schinkel A.H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Ther. 1 (2002) 427-434
19. Polgar O., Robey R.W., and Bates S.E. Bcrp: structure, function and role in drug response. Expert Opin. Drug Metab. Toxicol. 4 (2008) 1-15
20. Eisenblätter T., and Galla H.J. A new multidrug resistance protein at the blood-brain barrier. Biochem. Biophys. Res. Commun. 293 (2002) 1273-1278
21. Eisenblätter T., Hüwel S., and Galla H.J. Characterisation of the brain multidrug resistance protein (BMDP/Bcrp/BCRP) expressed at the blood-brain barrier. Brain Res. 971 (2003) 221-231
22. Cisternino S., Mercier C., Bourasset F., Roux F., and Scherrmann J.M. Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 64 (2004) 3296-3301
23. Zhang W., Mojsilovic-Petrovic J., Andrade M.F., Zhang H., Ball M., and Stanimirovic D.B. The expression and functional characterization of Bcrp in brain endothelial cells and vessels. FASEB J. 17 (2003) 2085-2087
24. Breedveld P., Pluim D., Cipriani G., Wielinga P., van Tellingen O., Schinkel A.H., and Schellens J.H. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 65 (2005) 2577-2582
25. Bihorel S., Camenisch G., Lemaire M., and Scherrmann J.M. Influence of breast cancer resistance protein (Abcg2) and P-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J. Neurochem. 102 (2007) 1749-17457
26. de Vries N.A., Zhao J., Kroon E., Buckle T., Beijnen J.H., and van Tellingen O. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin. Cancer Res. 13 (2007) 6440-6449
27. Enokizono J., Kusuhara H., Ose A., Schinkel A.H., and Sugiyama Y. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. Drug Metab. Dispos. 36 (2008) 995-1002
28. Enokizono J., Kusuhara H., and Sugiyama Y. Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens. Mol. Pharmacol. 72 (2007) 967-975
29. Krishnamurthy P., and Schuetz J.D. Role of Bcrp/BCRP in biology and medicine. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 381-410
30. Breedveld P., Beijnen J.H., and Schellens J.H. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol. Sci. 27 (2006) 17-24
31. Robey R.W., Honjo Y., van de Laar A., Miyake K., Regis J.T., Litman T., and Bates S.E. A functional assay for detection of the mitoxantrone resistance protein, MXR (Bcrp). Biochim. Biophys. Acta 1512 (2001) 171-182
32. Pavek P., Merino G., Wagenaar E., Bolscher E., Novotna M., Jonker J.W., and Schinkel A. Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther. 312 (2005) 144-152
33. Minderman H., Suvannasankha A., O'Loughlin K.L., Scheffer G.L., Scheper R.J., Robey R.W., and Baer M.R. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 48 (2002) 59-65
34. Saito H., Hirano H., and Ishikawa T. High-speed screening and quantitative SAR analysis of human ABC transporter ABCG2 for molecular modeling of anticancer drugs to circumvent multidrug resistance. Mini Rev. Med. Chem. 7 (2007) 1009-1018
35. Robey R.W., Steadman K., Polgar O., Morisaki K., Blayney M., Mistry P., and Bates S.E. Pheophorbide a is a specific probe for Bcrp function and inhibition. Cancer Res. 64 (2004) 1242-1246
36. Henrich C.J., Bokesch H.R., Dean M., Bates S.E., Robey R.W., Goncharova E.L., Wilson J.A., and McMahon J.B. A high-throughput cell-based assay for inhibitors of Bcrp activity. J. Biomol. Screen. 11 (2006) 176-183
37. Xiao Y., Davidson R., Smith A., Pereira D., Zhao S., Soglia J., Gebhard D., de Morais S., and Duignan D.B. A 96-well efflux assay to identify Bcrp substrates using a stably transfected MDCK II cell line. Mol. Pharm. 3 (2006) 45-54
38. Muenster U., Grieshop B., Ickenroth K., and Gnoth M.J. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm. Res. 35 (2008) 2320-2326
39. Glavinas H., Kis E., Pál A., Kovács R., Jani M., Vági E., Molnár E., Bánsághi S., Kele Z., Janáky T., Báthori G., von Richter O., Koomen G.J., and Krajcsi P. Bcrp (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions. Drug Metab. Dispos. 35 (2007) 1533-1542
40. Matsson P., Englund G., Ahlin G., Bergström C.A., Norinder U., and Artursson P. A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (Bcrp). J. Pharmacol. Exp. Ther. 323 (2007) 19-30
41. Huwyler J., Fricker G., Török M., Schneider M., and Drewe J. Transport of clonidine across cultured brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 282 (1997) 81-85
42. Begley D.J. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 10 (2004) 1295-1312
43. Cooray H.C., Blackmore C.G., Maskell L., and Barrand M.A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13 (2002) 2059-2063
44. Rocchi E., Khodjakov A., Volk E.L., Yang C.H., Litman T., Bates S.E., and Schneider E. The product of the ABC half-transporter gene Bcrp (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem. Biophys. Res. Commun. 271 (2000) 42-46
45. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., and Greenberger L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 60 (2000) 47-50
46. Pan G., and Elmquist W.F. Mitoxantrone permeability in MDCKII cells is influenced by active influx transport. Mol. Pharm. 4 (2007) 475-483
47. Tanigawara Y., Okamura N., Hirai M., Yasuhara M., Ueda K., Kioka N., Komano T., and Hori R. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J. Pharmacol. Exp. Ther. 263 (1992) 840-845
48. Gutmann H., Torok M., Fricker G., Huwyler J., Beglinger C., and Drewe J. Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro. Drug Metab. Dispos. 27 (1999) 937-941
49. Sykes D., Sweet D.H., Lowes S., Nigam S.K., Pritchard J.B., and Miller D.S. Organic anion transport in choroid plexus from wild-type and organic anion transporter 3 (Slc22a8)-null mice. Am. J. Physiol. Renal Physiol. 286 (2004) F972-F978
50. Kruijtzer C.M., Beijnen J.H., Rosing H., ten Bokkel Huinink W.W., Schot M., Jewell R.C., Paul E.M., and Schellens J.H. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20 (2002) 2943-2950
51. Allen J.D., van Loevezijn A., Lakhai J.M., van der Valk M., van Tellingen O., Reid G., Schellens J.H., Koomen G.J., and Schinkel A.H. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol. Cancer Ther. 1 (2002) 417-425
52. Zhang Y., Schuetz J.D., Elmquist W.F., and Miller D.W. Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells. J. Pharmacol. Exp. Ther. 311 (2004) 449-455
53. Kusuhara H., and Sugiyama Y. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2 (2005) 73-85
54. Löscher W., and Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 6 (2005) 591-602
55. Bates S.E., Robey R., Miyake K., Rao K., Ross D.D., and Litman T. The role of half-transporters in multidrug resistance. J. Bioenerg. Biomembr. 33 (2001) 503-511
56. Litman T., Brangi M., Hudson E., Fetsch P., Abati A., Ross D.D., Miyake K., Resau J.H., and Bates S.E. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci. 113 (2000) 2011-2021
57. Diah S.K., Smitherman P.K., Aldridge J., Volk E.L., Schneider E., Townsend A.J., and Morrow C.S. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res. 61 (2001) 5461-5467
58. Morrow C.S., Peklak-Scott C., Bishwokarma B., Kute T.E., Smitherman P.K., and Townsend A.J. Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol. Pharmacol. 69 (2006) 1499-1505
59. Litman T., Druley T.E., Stein W.D., and Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. 58 (2001) 931-959
60. Nielsen D., Eriksen J., Maare C., Litman T., Kjaersgaard E., Plesner T., et al. Characterisation of non-P-glycoprotein multidrug-resistant Ehrlich ascites tumour cells selected for resistance to mitoxantrone. Biochem. Pharmacol. 60 (2000) 363-370
61. Bubik M., Ott M., Mahringer A., and Fricker G. Rapid assessment of P-glycoprotein-drug interactions at the blood-brain barrier. Anal. Biochem. 358 (2006) 51-58
62. Boumendjel ] A., Nicolle E., Moraux T., Gerby B., Blanc M., Ronot X., and Boutonnat J. Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2). J. Med. Chem. 48 (2005) 7275-7281
63. Sugimoto Y., Tsukahara S., Imai Y., Sugimoto Y., Ueda K., and Tsuruo T. Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol. Cancer Ther. 2 (2003) 105-112
64. Zhang Y., Gupta A., Wang H., Zhou L., Vethanayagam R.R., Unadkat J.D., and Mao Q. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm. Res. 22 (2005) 2023-2034
65. Gupta A., Zhang Y., Unadkat J.D., and Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/Bcrp). J. Pharmacol. Exp. Ther. 310 (2004) 334-341
66. Imai Y., Tsukahara S., Asada S., and Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/Bcrp-mediated multidrug resistance. Cancer Res. 64 (2004) 4346-4352
67. Zhang S., Yang X., and Morris M.E. Flavonoids are inhibitors of breast cancer resistance protein (Bcrp)-mediated transport. Mol. Pharmacol. 65 (2004) 1208-1216
68. Gupta A., Dai Y., Vethanayagam R.R., Hebert M.F., Thummel K.E., Unadkat J.D., Ross D.D., and Mao Q. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (Bcrp) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother. Pharmacol. 58 (2006) 374-383
69. Shiozawa K., Oka M., Soda H., Yoshikawa M., Ikegami Y., Tsurutani J., Nakatomi K., Nakamura Y., Doi S., Kitazaki T., Mizuta Y., Murase K., Yoshida H., Ross D.D., and Kohno S. Reversal of breast cancer resistance protein (BCRP/Bcrp)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int. J. Cancer 108 (2004) 146-151
70. Nakamura Y., Oka M., Soda H., Shiozawa K., Yoshikawa M., et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/Bcrp-mediated drug resistance. Cancer Res. 65 (2005) 1541-1546
71. Gabrielsson J., and Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Application (1997), Swedish Pharmaceutical Society
72. Polli J.W., Wring S.A., Humphreys J.E., Huang L., Morgan J.B., Webster L.O., and Serabjit-Singh C.S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299 (2001) 6220-6628
73. Yang C., Chen Y.C., and Kuo M.L. Novobiocin sensitizes BCRP/MXR/ABCP over-expressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone. Anticancer Res. 23 (2003) 2519-2523
74. Imai Y., Tsukahara S., Ishikawa E., Tsuruo T., and Sugimoto Y. Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn. J. Cancer Res. 93 (2002) 231-235
75. Weiss J., Rose J., Storch C.H., Ketabi-Kiyanvash N., Sauer A., Haefeli W.E., and Efferth T. Modulation of human BCRP (Bcrp) activity by anti-HIV drugs. J. Antimicrob. Chemother. 59 (2007) 238-245
76. Zhang S., Yang X., and Morris M.E. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm. Res. 21 (2004) 1263-1273
77. Bauer B., Miller D.S., and Fricker G. Compound profiling for P-glycoprotein at the blood-brain barrier using a microplate screening system. Pharm. Res. 20 (2003) 1170-1176
78. Eneroth E., Åström E., Hoogstraate J., Schrenk D., Conrad S., Kauffmann H.-M., and Gjellan K. Evaluation of a vincristine resistant caco-2 cell line for use in a calcein-AM extrusion screening assay for P-glycoprotein interaction. Eur. J. Pharm. Sci. 12 (2001) 205-214
79. Tiberghien F., and Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-Cancer Drugs 7 (1996) 568-578